Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : American Bio Medica (ABMC) drug test solution -taking off! -- Ignore unavailable to you. Want to Upgrade?

To: Skywatcher who wrote (555)	9/16/1999 10:45:00 AM
From: TScott	Read Replies (1) \| Respond to of 629

Is this GOOD NEWS or what!!! and.... the market agrees :-) KINDERHOOK, N.Y., Sep 16, 1999 (BUSINESS WIRE) -- American Bio Medica Corp. (NASDAQ: ABMC) announced today that its successful appeal to the Court of Special Appeals of Maryland resulted in the reversal of a 1998 decision by a trial court judge to award the Robert Friedenberg estate 5,907,514 common shares of ABMC stock. The Court agreed that the trial judge erred in awarding the ABMC shares to Friedenberg's estate. The Company explained that Friedenberg was to receive the shares from ABMC in exchange for providing to American Bio Medica certain technology, which he never delivered. A jury earlier decided in the Company's favor on claims of breach of contract and fraud. Thus, the Company refused to issue stock to Friedenberg. "Needless to say, we are very excited to report the court's decision and pleased to have the appeal finally behind us," stated ABMC Chairman and CEO Stan Cipkowski. "The positive results of this outcome are clear: our litigation risk is reduced substantially and our bottom line will be impacted positively." American Bio Medica Corporation develops, manufactures, and markets inexpensive, accurate, on-site drugs of abuse diagnostic kits and support services worldwide. The Company's global distributors target the workplace, clinical, rehabilitation, physicians, corrections, and educational markets. ABMC's Rapid Drug Screen(TM) is proven to correlate 100% with the standard laboratory screening test. Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic report filed with the Securities and Exchange Commission.